Diabeloop won CE Mark clearance in the European Union this month for its hybrid closed-loop diabetes management system, DBLG1. The Paris-based company hopes to launch its “artificial pancreas” system for adults with Type I diabetes in Europe by the second quarter in 2019. Get the full story at our sister site, Drug Delivery Business News.
As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to the potential of closed-loop insulin delivery systems. Major medical technology companies, including Medtronic and Insulet, touted data at this year’s meeting demonstrating the benefits of their […]
Cellnovo (EPA:CLNV) and Diabeloop said this week they are launching a CE Mark cross-over registration study for an artificial pancreas device Diabeloop is developing which uses Cellnovo’s insulin pump. The registration study aims to generate appropriate security & safety data as the company seeks CE Mark approval for the Diabeloop artificial pancreas combined with Cellnovo’s CGM some […]